Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon-beta-1b - Toray/Daiichi Sankyo

Drug Profile

Interferon-beta-1b - Toray/Daiichi Sankyo

Alternative Names: DL-8234; Feron; Interferon-beta-1b

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toray
  • Developer Daiichi Sankyo Company; Toray
  • Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Brain cancer; Glioblastoma; Hepatitis B; Hepatitis C; Malignant melanoma
  • Registered Liver cirrhosis
  • Discontinued Age-related macular degeneration; Liver cancer

Most Recent Events

  • 24 Mar 2015 The product is approved for Cirrhosis in Japan
  • 16 Oct 2009 Registered for Hepatitis C in combination with ribavirin in Japan (IV)
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top